Pfizer Stock News

Sean Gallup/Getty Images News Pfizer (NYSE:PFE) announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent

DUBLIN , Jan. 12, 2022 /PRNewswire/ -- The "Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021" report has been added to ResearchAndMarkets.com''s offering. The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014- 2021 report provides comprehensive access to available deals and contract documents for over 2,900 clinical stage deals. The report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector. Understanding the flexibility of a prospective partner''s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

Pfizer is ready to provide 50 million to 100 million vaccine doses for people who are found positive with the omicron variant of the coronavirus if it is needed.

Bill Gates Flip Flops After Turning Omicron ''FUD'' Up To ''11'' After initially turning the "FUD" dial up to ''11'' in response to the initial reports and data about the omicron variant, Microsoft founder and billionaire wannabe global vaccine czar Bill Gates has apparently had a change of heart. Gates on Tuesday joined Professor Devi Sridhar, a professor and chair of global health policy at the University of Edinburgh, for a Twitter discussion about the COVID pandemic. Following a few questions about vaccines where Gates seems to actually acknowledge their shortcomings for once, Gates tells Dr. Sridhar that after an omicron wave has subsided, the rest of the year should see far fewer cases and deaths, leaving COVID to retreat to the intensity of a bad flu. "Once Omicron goes through a country then the rest of the year should see far fewer cases so Covid can be treated more like seasonal flu." A more infectious variant is "not likely," according to Gates, although he acknowledges that the world has been "surprised a lot" before, and that the WHO is already hard at work trying to prepare for the "next" pandemic.

After The Storm Authored by Raúl Ilargi Meijer via The Automatic Earth blog, With Omicron taking over at lightning speed, and what we know about it from South Africa and Denmark, it would seem that we can relax. It’s reported to be 100x less deadly than Alpha/Delta, and perhaps less deadly than the common flu. If you’ve had Alpha/Delta, you can still get Omicron, but an Omicron infection appears to make you immune to Alpha/Delta. As far as we can see, nobody’s dying from Omicron, intubations are rare at best, and positive tests, even if they do end up in hospital, are mostly released as fast as they came in. It’s simply over. It’ll take another few weeks for this to become impossible to ignore, but it’s already there. A number of voices have called for treating it like the flu; Spain appears to have made that its official policy. It’s over. And media, politicians and “experts” will need to jockey for position. They will not apologize for all the fear induced, or the human rights broken, they will make you believe that their new position is perfectly in line with what they’ve done over the past two years, and all that has changed is “The Science”.

A source to Reuters that Pfizer was eliminating a few hundred positions.

A new real-world study funded by the Department of Veterans Affairs (VA) showed that compared to those who received Pfizer Inc''s (NYSE: PFE ) COVID-19 vaccine, Moderna Inc (NASDAQ: MRNA ) vaccine recipients had a significantly lower risk of SARS-CoV-2 infection and related hospitalizations . Lower risk was observed across all age groups, comorbidity-burden categories, and Full story available on Benzinga.com

Dren Bio has brokered a research collaboration and license arrangement with Pfizer that could be worth more than $1B to the privately held biotech.

''Urgent Reset Needed'': Democratic Insiders Come Forward To Admit Biden Admin Has ''Gone Backwards'' On COVID Policy Approximately half a dozen former health policymakers - including members of Biden''s transition team - have come forward to declare that the Biden administration''s Covid-19 policy has gone off the rails and needs an ''urgent strategy reset.'' President Joe Biden is urging schools to stay open, but theres a widespread Covid testing shortage . He calls it the pandemic of the unvaccinated, but thats only confused boosted Americans home sick with the omicron variant. And the administration hasnt changed its guidance to urge high-filtration masks despite calls from the medical community, while recent isolation guidance has only added to the uncertainty . - NBC News Indeed, current policy now seems to be a shoot-from-the-hip combination of bad kneejerk policy based on early pandemic response and deadlier strains (primarily affecting the elderly and those with multiple comorbidities , as CDC Director Rochelle Walensky recently admitted) - and new policy which doubles down on vaccination against a new strain despite its far more mild presentation and vaccine evasion.

Futures Rebound As Fed-Induced Rout Finally Eases After yesterday''s miraculous tech recovery which saw gigacaps drop as much as 4% before recovering all losses and closing green, Nasdaq futures led gains among U.S. stock-index futures, hinting at further relief for technology stocks as Treasury yields retreated in early trading but have since steadied around 1.75%, unchanged from Monday. Nasdaq futures rose as much as 0.7%, while S&P 500 and Dow Jones contracts were also higher by about 0.4% ahead of Powells Senate confirmation hearing for second term as Fed chair which begins at 10am and where the Fed chair is expected to put on a dovish mask and walk back some of the recent hawkish commentary. Dip-buyers rescued the Nasdaq from a fifth session of declines on Monday after Marko Kolanovic urged JPM clients to buy the dip, writing that yields aren''t too high and the Fed''s won''t derail the economys rebound. We view the recent equity volatility as an adjustment to the Feds incrementally more hawkish stance, rather than a sign that the Fed is about to bring the recovery and the equity rally abruptly to an end, Mark Haefele, chief investment officer at UBS Global Wealth Management, said in a note. We now expect three Fed rate hikes this year, starting as soon as March. We are looking for opportunities to raise our weighting in stocks in 2022, according to Luca Paolini, chief strategist at Pictet Asset Management, whose firm has a neutral stance on equities. The global recovery remains resilient, thanks to a strong labor market, pent-up demand for services and healthy corporate balance sheets. In his second term confirmation hearing before the Senate Banking Committee at 10am ET today, Fed Chair Jerome Powell will say the central bank will keep inflation from becoming entrenched, but the post-pandemic economy may look different from previous expansions.

Another antiviral drug used for the treatment Covid-19 patients will soon be made locally available, according to the

Omicron covid vaccine: This vaccine will be ready in March, Pfizer Chief Executive Officer Albert Bourla said

Pfizer is also making inroads in scaling out access to its oral Covid-19 treatment, Paxlovid

The push to boost every person in the United States has a scientific problem. New data show that vaccine booster efficacy against getting COVID can plummet to 35% with the Pfizer booster and 45% with the Moderna booster just 10 weeks after that third shot. So will public-health officials recommend boosters every three months in

Pfizer (PFE) has won a $442.13M modification (P00001) to a U.S. Army contract to produce 835,000 PAXLOVID.